The new class of ESIPT-capable molecules, benzo[a]imidazo[5,1,2-cd]indolizines, bearing the 2-hydroxyphenyl substituent were prepared in a straightforward manner from imidazo[1,2-a]pyridines via a tandem [8+2]cycloaddition–[2+6+2]dehydrogenation reaction. The relationship between the structure and photophysical properties was thoroughly elucidated by comparison with simple analogues i.e. 2-(2′-hydroxyphenyl)imidazo[1,2-a]pyridines. Compared with parent 2-(2′-hydroxyphenyl)imidazo[1,2-a]pyridines the new chromophores strongly absorb blue light and emit in the yellow part of the spectrum. In contrast to 2-(2′-hydroxyphenyl)imidazo[1,2-a]pyridines, emission of π-expanded dyes in protic solvents is usually weaker than in aprotic ones, where they exhibit large Stokes shifts (5500–7000 cm−1). Unlike in solution, in the solid state luminescence for benzo[a]imidazo[5,1,2-cd]indolizines is shifted on average by 100 nm relative to the fluorescence of the corresponding imidazo[1,2-a]pyridines, which results in a relatively strong (Φfl = 0.18 to 0.27) emission of the red light. Benzo[a]imidazo[5,1,2-cd]indolizines possessing a methoxy substituent have much higher fluorescence quantum yields than analogues bearing fluorine and methyl substituents.
No takes yet. Share an insight, caveat, or question.
Stasyuk et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: